Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum

Journal of Neuroscience

Volumn 22, Issue 5, 2002, Pages 1967-1975

  Popoli, Patrizia ^a   Pintor, Annita ^a   Domenici, Maria Rosaria ^a   Frank, Claudio ^a   Tebano, Maria Teresa ^a   Pèzzola, Antonella ^a   Scarchilli, Laura ^a   Quarta, Davide ^a   Reggio, Rosaria ^a   Malchiodi Albedi, Fiorella ^a   Falchi, Mario ^a   Massotti, Marino ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adenosine A2A receptors; Huntington's disease; Neuroprotection; Quinolinic acid; SCH 58261; Striatum

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; CALCIUM ION; DIZOCILPINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUINOLINIC ACID;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG INHIBITION; ELECTROENCEPHALOGRAM; GLIOSIS; HUNTINGTON CHOREA; MALE; MOTOR ACTIVITY; NEUROPROTECTION; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

EID: 0036522987     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-05-01967.2002     Document Type: Article

References (56)

1. Abbracchio MP, Cattabeni A (1999) Brain adenosine receptors as target for therapeutic intervention in neurodegenerative diseases. Ann NY Acad Sci 890:79-92.
2. Bamford KA, Caine ED, Kido DK, Cox C, Shoulson I (1995) A prospective evaluation of cognitive decline in early Huntington's disease: Functional and radiographic correlates. Neurology 45:1867-1873.
3. Bates GP, Mangiarini L, Mahal A, Davies SW (1997) Transgenic mouse models of Huntington's disease. Hum Mol Genet 6:1633-1637.
4. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:168-171.
5. Block F, Kunkel M, Schwartz M (1993) Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performances in rats. Neurosci Lett 149:126-128.
6. Bona E, Adén U, Giland E, Fredholm BB, Hagberg H (1997) Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists. Neuropharmacology 36:1327-1338.
7. Bylsma FW, Peyser CE, Folstein SE, Ross C, Brandt J (1994) EEG power spectra in Huntington's disease: Clinical and neuropsychological correlates. Neuropsychologia 32:137-150.
8. Calabresi P, Picconi B, Saulle E, Centonze D, Hainsworth A, Bernardi G (2000) Is pharmacological neuroprotection dependent on reduced glutamate release? Stroke 31:766-773.
9. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192-9200.
10. 2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143(1-6).
11. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.
12. Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13:171-182.
13. Connick JH, Stone TW (1988) Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol 93:868-876.
14. +-evoked glutamate release in vivo in young and aged rats. NeuroReport 10:687-691.
15. 2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young, aged rats NeuroReport 11:2591-2595.
16. Devan BD, White NM (1999) Parallel information processing in the dorsal striatum: Relation to hippocampal function, J Neurosci 19:2789-2798.
17. Dionisotti S, Zocchi C, Varani K, Borea PA, Ongini E (1992) Effects of adenosine derivatives on human and rabbit platelet aggregation. Correlation of adenosine receptor affinities and antiaggregatory activity. Naunyn Schmiedebergs Arch Pharmacol 346:673-676.
18. 3H]SCH 58261. Eur J Neurosci 14:1567-1570.
19. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosinedopamine receptor-receptor interactions in the basal ganglia. Trends Neurosci 20:482-487.
20. Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, Gebicke-Haerter PJ (1996) Cyclooxygenase-e expression in rat microglia is induced by adenosine A2a-receptors. Glia 18:152-160.
21. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M (1994) Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156.
22. 2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbil. Life Sci 55:PL61-PL65.
23. Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97:505-519.
24. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-192.
25. Impagnatiello F, Bastia E, Ongini E, Monopoli A (2000) Adenosine receptors in neurological disorders. Emerg Ther Targets 4:635-664.
26. 2A receptor agonists and antagonists. Neuroscience 85:229-237.
27. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinstein DC, Robbins TW, Sahakien BJ (1998) Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 121:1329-1341.
28. 2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 354:539-541.
29. 1 receptor responses. Eur J Pharmacol 383:395-398.
30. Marshall FJ, Shoulson I (1997) Clinical features and treatment of Huntington's disease. In: Movement Disorders: Neurologic Principles and Practice (Watt RL, Koller WC, eds), pp 491-502. New York: McGraw-Hill.
31. Mauler F, Fahrig T, Horvath E, Jork R (2001) Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo. Brain Res 888:150-157.
32. Mena FV, Baab PJ, Zielke CL, Zielke HR (2000) In vivo glutamine hydrolysis in the formation of extracellular glutamate in the injured rat brain. J Neurosci Res 60:632-641.
33. 2A adenosine receptor antagonist, SCH 58261, in the rat. J Pharmacol Exp Ther 285:9-15.
34. 2A receptors results in neuroprotective effects in cerebral ischaemia in rats. NeuroReport 9:3955-3959.
35. Nöremberg W, Wirkner K, Illes P (1997) Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. Br J Pharmacol 122:71-80.
36. Obrenovitch TP, Urenjak J, Zilkha E, Jay TM (2000) Excitotoxicity in neurological disorders: The glutamate paradox. Int J Dev Neurosci 18:281-287.
37. O'Neill MJ, Bogaert L, Hicks CA, Bond A, Ward MA, Ebinger G, Ornstein PL, Michotte Y, Lodge D (2000) LY 377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global, focal cerebral ischaemia Neuropharmacology 39:1575-1588.
38. 1 or blocking A2A adenosine receptors: An apparent paradox. Drug Dev Res 45:387-393.
39. 2A receptors and neuroprotection. Ann NY Acad Sci 825:30-48.
40. Orlando LR, Alsdorf SA, Penney Jr JB, Young AB (2001) The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp Neurol 167:196-204.
41. 2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 705:79-84.
42. Phillis JW, Wu PH (1981) The role of adenosine and its nucleotides in central synaptic transmission. Prog Neurobiol 16:187-239.
43. Picano E, Abbracchio MP (2000) Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. Brain Res Bull 52:75-82.
44. Popoli P, Pezzola A, Domenici MR, Sagratella S, Diana G, Caporali MG, Bronzetti E, Vega J, Scotti de Carolis A (1994) Behavioural and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease. Brain Res Bull 35:329-335.
45. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 287:215-217.
46. 2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res 831:315-318.
47. Rossi DJ, Oshima T, Attwell D (2000) Glutamate release in severe brain ischaemla is mainly by reversed uptake. Nature 403:316-321.
48. Rozas G, Liste I, Lopez-Martin E, Guerra MJ, Kokaia M, Labandiera-Garcia JL (1996) Intrathalamic implants of GABA-releasing polymer matrices reduce motor impairments in rats with excitotoxically lesioned striata. Exp Neurol 142:323-330.
49. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. J Neurochem 57:1062-1067.
50. Schwarz M, Block F, Topper R, Sontag KH, Noth J (1992) Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: Evidence that basal ganglia modulate sensory cortical input. Ann Neurol 32:358-364.
51. Stella L, De Novellis V, Berrino L, d'Amico M, Rossi F (1996) Evidence that A(2a) and not A(2b) purinoceptors are coupled to production of nitric oxide in the regulation of blood pressure. Environ Toxicol Pharmacol 2:327-329.
52. Stone TW (1993) Neuropharmacology of quinolinic and kinurenic acids. Pharmacol Rev 45:309-379.
53. Stone TW (2001) Endogenous neurotoxins from tryptophan. Toxicon 39:61-73.
54. Varani K, Cacciari B, Baraldi PG, Dionisotti S, Ongini E, Borea PA (1998) Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors. Life Sci 63:PL81-PL87.
55. 2A receptor signaling in striatal cells expressing mutant huntingtin. FASEB J 15:1245-1247.
56. 2A receptor antagonists. J Pharmacol Exp Ther 276:398-404.